GenSight Biologics to highlight gene therapies at Cell & Gene Meeting

By The Science Advisory Board staff writers

French biotechnology firm GenSight Biologics is highlighting its lenadogene neparvovec (Lumevoq) and GS030 gene therapies at the Cell & Gene Meeting on the Mesa in Carlsbad, CA.

Dr. Magali Taiel, the company's chief medical officer, will present virtually during a prerecorded session on developments in the pipeline for the two therapies. Lumevoq is designed to treat vision loss caused by Leber hereditary optic neuropathy, while GS030 is for retinitis pigmentosa.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking